Editor: José Juan Antonio Ibarra Arias

Frontiers in Clinical Drug Research – Dementia

Volume 2

eBook: US $69 Special Offer (PDF + Printed Copy): US $124
Printed Copy: US $90
Library License: US $276
ISSN: 2717-5987 (Print)
ISSN: 2717-5995 (Online)
ISBN: 978-981-5039-48-1 (Print)
ISBN: 978-981-5039-47-4 (Online)
Year of Publication: 2021
DOI: 10.2174/97898150394741210201


Among neurodegenerative diseases, those that lead to a state of dementia are the aim of several investigations. Dementia is a chronic disease the prevalence of which is increasing worldwide. The number of dementia patients in the world is approximately 50 million, and it is estimated that the number of patients will reach 131.5 million by 2050. This increase will be accompanied by a significant increase in medical expenditures and other expenses, especially for elderly patients. Therefore, the maintenance cost of dementia in the future is expected to be quite high. For this reason, several investigations aim, firstly, to describe the key mechanisms involved in the origin of dementia and, secondly, to establish preventive and therapeutic strategies in order to understand and mitigate this debilitating pathology.

This volume of Frontiers in Clinical Drug Research - Dementia explores the current comorbidities that cause cognitive impairment and the current management alternatives for clinical cases of dementia. The reviews contributed in these volume will provide readers with a current perspective on the subject. The topics covered in this volume include:

  • - Comorbidities inducing mild cognitive impairment - an evaluation of the risk caused by some pathological conditions
  • - Tau-targeted therapy in Alzheimer's disease - history and current state
  • - Emerging nanotherapeutic strategies in Alzheimer's disease
  • - Implication of dehydroepiandrosterone on dementia related to oxidative stress
  • - Polyphenol compounds as potential therapeutic agents in Alzheimer’s disease

The volume is a timely update on dementia treatment for clinical physicians, neurologists, gerontologists, pharmaceutical and medicinal chemistry researchers, and physiologists.

Audience: clinical physicians, neurologists, gerontologists, pharmaceutical and medicinal chemistry researchers, and physiologists.


- Pp. i
José Juan Antonio Ibarra Arias
Download Free

List of Contributors

- Pp. ii-iv (3)

Download Free

Comorbidities Inducing Mild Cognitive Impairment, an Evaluation of the Risk Caused by some Pathological Conditions

- Pp. 1-55 (55)
Yolanda Cruz, Alejandra Romo, Roxana Rodríguez-Barrera, Almudena Chávez-Guerra, Macarena Fuentes, Antonio Ibarra*
View Abstract

Tau-Targeted Therapy in Alzheimer's Disease - History and Current State

- Pp. 56-139 (84)
Anamaria Jurcau*, Vharoon Sharma Nunkoo
View Abstract

Implication of Dehydroepiandrosterone on Dementia Related to Oxidative Stress

- Pp. 140-172 (33)
Adriane Bello Klein, Alexandre Castro, Alex Sander da Rosa Araujo, Daiane da Rocha Janner, Maria Helena Vianna Metello Jacob*
View Abstract

Emerging Nanotherapeutic Strategies in Alzheimer's Disease

- Pp. 173-203 (31)
Soheila Montazersaheb, Elham Ahmadian, Solmaz Maleki Dizaj, Yalda Jahanbani, Soodabeh Davaran, Irada Huseynova, Cumali Keskin, Renad I. Zhdanov, Rovshan Khalilov, Aziz Eftekhari*
View Abstract

Polyphenol Compounds as Potential Therapeutic Agents in Alzheimer’s Disease

- Pp. 204-255 (52)
Érika Paiva de Moura, Alex France Messias Monteiro, Natan Dias Fernandes, Herbert Igor Rodrigues de Medeiros, Igor José dos Santos Nascimentos, Marcus Tullius Scotti, Francisco Jaime Bezerra Mendonça Júnior, Edeildo Ferreira da Silva-Júnior*, Luciana Scotti
View Abstract

Subject Index

- Pp. 256-263 (8)

Download Free